Jason Aryeh is Director at LIGAND PHARMACEUTICALS INC (LGND). They have made 83 open-market trades across 9 companies since 2007, most recently 2026-06-11.
CIK 0001376960
41 open-market purchases totalling $7.4M since 2007, against 42 sales. Across 27 scored buys the stock is up 1.3% at ninety days, and 0.4 points behind the S&P over the same stretch.
27 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 26% | 37% | 26% |
| Avg Move | -4.5% | +2.0% | +1.3% |
| Alpha | -1.8% | +1.6% | -0.4% |
| Scored | 27 | 27 | 27 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LGND | SELL | 2026-06-10 | 2026-06-12 | $250.00 | $1.3M | +16.1% | +21.8% | +13.5% |
| OBIO | BUY | 2026-05-18 | 2026-05-20 | $3.75 | $2K | -3.6% | +1.0% | +41.4% |
| OBIO | BUY | 2026-05-15 | 2026-05-19 | $3.90 | $35K | -2.9% | +0.6% | +19.1% |
| LGND | SELL | 2025-09-23 | 2025-09-24 | $170.81 | $3.4M | +8.7% | +11.3% | +17.5% |
| OBIO | BUY | 2025-09-19 | 2025-09-19 | $2.45 | $2K | +4.5% | +59.8% | +77.9% |
| LGND | BUY | 2019-09-03 | 2019-09-04 | $87.01 | $131K | +14.2% | +14.4% | +24.5% |
| LGND | BUY | 2019-08-05 | 2019-08-06 | $90.01 | $134K | +5.1% | -1.0% | +22.1% |
| LGND | BUY | 2019-07-29 | 2019-07-31 | $99.22 | $397K | -2.6% | -2.6% | +20.5% |
| MACK | BUY | 2019-07-16 | 2019-07-18 | $5.44 | $2K | +19.7% | +19.9% | -22.9% |
| MACK | BUY | 2019-07-11 | 2019-07-15 | $5.68 | $20K | +3.4% | +16.2% | -26.3% |
| LGND | BUY | 2019-06-11 | 2019-06-12 | $107.01 | $27K | -1.0% | +4.7% | -18.7% |
| LGND | BUY | 2019-05-29 | 2019-05-31 | $109.51 | $110K | +1.4% | +5.5% | -15.8% |
| LGND | BUY | 2019-05-20 | 2019-05-22 | $112.01 | $28K | +0.9% | -1.7% | -15.9% |
| LGND | BUY | 2019-05-14 | 2019-05-16 | $112.51 | $28K | -3.5% | -3.2% | -18.6% |
| LGND | BUY | 2019-03-13 | 2019-03-15 | $112.51 | $23K | +0.7% | +4.8% | -5.2% |
| LGND | SELL | 2018-08-16 | 2018-08-17 | $241.87 | $13.3M | +3.4% | +2.2% | -38.8% |
| LGND | SELL | 2018-03-08 | 2018-03-09 | $175.73 | $1.3M | -6.8% | -11.7% | +11.1% |
| LGND | SELL | 2018-02-23 | 2018-02-27 | $155.00 | $530K | +16.1% | +9.0% | +23.4% |
| LGND | SELL | 2017-11-17 | 2017-11-20 | $140.22 | $3.4M | +0.2% | +4.6% | +19.3% |
| LGND | SELL | 2017-08-23 | 2017-08-25 | $127.99 | $256K | +8.7% | +9.0% | +7.3% |
| ARLZ | SELL | 2017-05-19 | 2017-05-24 | $1.44 | $1.1M | -9.2% | -6.4% | -18.4% |
| NVLN | BUY | 2017-05-15 | 2017-05-17 | $8.95 | $3K | -6.0% | +0.2% | -16.7% |
| LGND | SELL | 2017-05-11 | 2017-05-12 | $110.76 | $8.3M | +0.2% | +1.4% | +10.4% |
| LGND | SELL | 2017-02-27 | 2017-02-28 | $106.35 | $3.4M | +3.3% | -0.7% | +3.0% |
| LGND | SELL | 2016-11-22 | 2016-11-25 | $107.32 | $4.0M | -3.3% | -2.8% | -3.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| NABI |
| 131,783 |
| — |
| MYRX | 545,245 | — |
| QLT | 153,578 | — |
| LGNDD | 5,025 | — |
| Total | $43.8M |
Shares reported on the most recent Form 4, priced at the 2026-06-12 close. 4 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.